Gruenenthal Gmbh
Grünenthal is a privately owned pharmaceutical group headquartered in Aachen, Germany, focused on pain management and related diseases through research, development, manufacturing and commercialisation of medicines. Its research programme emphasises novel non-opioid treatments, drawing on expertise in neurobiology, sensory biology, neuronal health and neuroinflammation to develop candidates for pain and adjacent conditions. The group combines internally developed products with acquired medicines and business development agreements, and its published profile describes research sites in Aachen and Boston. Its corporate information reports commercial affiliates in twenty-eight countries across Europe, Latin America and the United States, with products available in approximately one hundred countries worldwide. In 2024, Grünenthal acquired US-based Valinor Pharma and its product Movantik, followed in 2025 by rights to Cialis in Mexico, Brazil and Colombia. The company reported revenue of €1.8 billion and approximately 4,100 employees for 2025, and its corporate history records the move to full ownership of Grünenthal Meds in 2026 after the earlier joint venture with Kyowa Kirin.
5 of the funds FundTelligence covers report a position in Gruenenthal Gmbh.
- Sector
- Health Care
- Country
- Germany
- Funds holding it
- 5
Funds holding Gruenenthal Gmbh
- Nordea European Cross Credit ESG Fund — Nordea Funds · 1.68 % (full portfolio disclosed, July 2026)
- Pareto ESG Global Corporate Bond — Pareto · 1.59 % (full portfolio disclosed, June 2026)
- Danske Invest Euro High Yield Obligasjon — Danske Invest · 0.4 % (full portfolio disclosed, September 2026)
- Danske Invest Global High Yield Obligasjon — Danske Invest · 0.18 % (full portfolio disclosed, September 2026)
- Alfred Berg Global High Yield — Alfred Berg · 0.13 % (full portfolio disclosed, June 2026)